PUL-042 for Viral Lung Infections in Blood Cancers and Stem Cell Transplant Patients
This study is testing an experimental drug called PUL-042 Inhalation Solution to see if it can help reduce severe lung infections. These infections are caused by parainfluenza virus (PIV), human metapneumovirus (hMPV), or respiratory syncytial virus (RSV). You may be able to join if you have a blood cancer (hematologic malignancy) or have received a stem cell transplant (hematopoietic stem cell transplant, HSCT) and have one of these viral infections. The study aims to see if PUL-042 can prevent lower respiratory tract complications (LRTC), which are serious lung problems, within 28 days. The current status of this study is unclear.
- Study design
- This study plans to enroll up to 100 participants. You would be randomly assigned to receive either PUL-042 or a placebo (an inactive substance that looks the same).
- What's involved
- You would receive PUL-042 or placebo three times over a 6-day period. The total study duration for you would be about 30 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your lung health will be checked for lower respiratory tract complications for 28 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
At a glance
Conditions
Where it's being run
12 sites across 12 statesStudy leadership
- Colin Broom, MD · PRINCIPAL_INVESTIGATOR · Pulmotect, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Efficacy of PUL-042 Inhalation Solution on Lower Respiratory Tract Complications (LRTC)28 days
Determine efficacy of PUL-042 Inhalation Solution on lower respiratory tract complications (LRTC) using the peak post-treatment radiologic severity index (RSI) score in subjects with hematologic malignancies (HM \[lymphoma, multiple myeloma and leukemia\]) and hematopoietic stem cell transplant (HSCT) recipients with documented parainfluenza virus (PIV), human metapneumovirus (hMPV), or respiratory syncytial virus (RSV) infection. The RSI is a quantitative score based on the presence of pulmonary infiltrates in three zones in both lungs, a total of six zones. Normal in all zones would be a score of zero with a maximum score of 72, which represents total consolidation in all six zones.